Cambridge Healthtech Institute’s 6th Annual
Targeting MASH & Obesity
September 23,-24 2025
The recent success of weight-loss drugs that were originally developed for diabetes, has refocused drug discovery attention on obesity-related drug modalities, especially in the area of peptide-based therapeutics. The even more recent launch of the first therapeutic option for MASH, metabolic dysfunction-associated steatohepatitis, a form of fatty liver disease, has solidified drug discovery activity in the 'metabolic' field. At CHI’s Targeting MASH & Obesity conference, a continuation of the industry’s first NASH-focused conference, we will explore the drug discovery and development innovations fueling the resurgence of GLP1-and incretin-related peptides and also will cover small molecule therapeutics advancing in the pipeline for metabolic-related conditions. New drug targets in both MASH and obesity and their connections will also be explored.
Who should attend: Industry and academic discovery scientists in departments such as: in vitro Pharmacology, Peptide Therapeutics, Molecular Pharmacology, Diabetes, Metabolic Diseases, Liver Disease, Peptide Chemistry, Medicinal Chemistry, Small Molecule Therapeutics
Coverage will include, but is not limited to:
- GLP1-related peptide agonist progress
- Incretin-targeted small molecule drug leads
- Impact of MASH compounds in development on weight loss
- Impact of obesity-related compound on MASH
- New MASH targets and therapeutic modalities
- New obesity targets and therapeutic modalities
- Drug development challenges: diagnosis/endpoints/biomarkers
The deadline for priority consideration is March 7, 2025.
All proposals are subject to review by session chairpersons and/or the Scientific Advisory Committee to ensure the overall quality of the conference program. Additionally, as per Cambridge Healthtech Institute’s policy, a select number of vendors and consultants who provide products and services will be offered opportunities for podium presentation slots based on a variety of Corporate Sponsorships.
Opportunities for Participation: